Bugworks Research Inc. and Cytecare Cancer Hospitals Announce Collaboration to Accelerate Development of Advanced Immuno-oncology Therapies | PR Newswire

  • Bugworks – USA, India and Australia founded startup with world-renowned expertise in drug discovery, created a special Ex Vivo Immuno-Oncology Research Laboratory at Cytecare Hospital in Bengaluru.
  • The lab bridges the gap from discovery to development by addressing multiple intractable cancers such as gastric, rectal, renal cell, breast, head and neck, non-small cell lung cancer.
  • This partnership between a leading drug discovery company and a leading cancer hospital paves the way for the development of new immuno-oncology drugs that can be effective in a wider range of patients.
  • The outcome of this translational study will guide the first human trials, which are expected to begin in early 2024.

BENGALURU, India, September 19, 2022 /PRNewswire/ — Bugworks Research Inc., a clinical-stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration. Bugworks develops best-in-class new treatments for cancer and infectious diseases and has established a dedicated research center as part of Cytecare, which is committed to excellence in cancer care.

Bringing together a leading innovator in drug discovery and a state-of-the-art cancer hospital promises to be a game-changer in saving countless lives. Bugworks’ drug discovery engine, combined with Cytecare’s excellence in achieving optimal clinical outcomes, offers differentiated solutions for patients worldwide.

Commenting on the importance of this strategic cooperation, Suresh Ramuco-founder and CEO of Cytecare Cancer Hospitals, said: “We are delighted to partner with Bugworks Research in this inspiring work to discover new treatments for various types of cancer. In 2016, we began with a vision to build the nation’s best cancer care facility with the support of India– data of specific studies. At Cytecare, we strive to provide the best treatment for patients and support cutting-edge research. We strongly believe that accessible and affordable immuno-oncology therapy can come with India and be accessible to all patients. This collaboration heralds a bold new beginning for a healthier future.”

Bugworks’ current immuno-oncology research focuses on tumor microenvironment modulation involving adenosine antagonism, an area of ​​research that applies to many solid tumors. Drug candidates from this study will undergo translational testing in patient-derived tumors ex vivo laboratories of Cytecare before proceeding to first human clinical trials.

Dr. V. Balasubramanian, Co-Founder and Chief Operating Officer, Bugworksnoted, “We are discovering novel highly differentiated small-molecule immunotherapeutics that target the immunosuppressive microenvironment that promotes tumor growth. ex vivo laboratories at Cytecare oncology hospitals, as part of our collaboration, will greatly help to translate our research into a high percentage of successful clinical results.”

Currently, immunotherapy is an important mainstay in cancer treatment. Currently approved drugs do save lives, although only for a small proportion of patients. Bugworks’ approach in collaboration with Cytecare Hospitals offers new ways to increase the percentage of patients who benefit from these vital immunotherapies. The current collaboration is a small but significant step in helping India to become a biotech powerhouse.

About Bugworks Research (www.bugworksresearch.com)

Bugworks Research is a clinical-stage biopharmaceutical company developing novel therapeutics to combat antimicrobial resistance (AMR) and immunotherapy for the treatment of cancer patients using innovative structure-directed medicinal chemistry. Its AMR asset, BWC0977, currently in Phase 1 human studies, will address serious nosocomial, community-acquired and biologic bacterial infections. Its immuno-oncology pipeline is in preclinical development and has the potential to treat multiple cancers.

About Cytecare Cancer Hospitals (www.cytecare.com)

In November 2016 in Yelahanka, Bengaluru. Founded on the principle of “Taking Cancer Right,” Cytecare houses some of the nation’s best surgeons, physicians, oncologists, radiation oncologists and other clinical experts in its world-class facility. A hallmark of treatment at Cytecare is patient-centeredness, and today their comprehensive clinical team provides holistic care across a variety of medical specialties. Cytecare is also part of numerous global clinical trials that provide ongoing education and improved clinical outcomes for patients. Cytecare provides a consistently high level of specialized care to thousands of cancer patients from more than 40 countries.

For questions contact:

Pradeep Fernandes

pradeep@bugworksresearch.com

Logo: https://mma.prnewswire.com/media/1491889/Bugworks_Logo.jpg

Logo: https://mma.prnewswire.com/media/1898406/CYTECARE_HOSPITALS_Logo.jpg

Browse original content to download media:https://www.prnewswire.com/news-releases/bugworks-research-inc-and-cytecare-cancer-hospitals-announce-collaboration-to-accelerate-the-development-of-cutting-edge-immuno-oncology- therapy-301623949.html

SOURCE Bugworks

Source link